Nseir, SaadMartin-Loeches, IgnacioPovoa, PedroPovoa, PedroMetzelard, MatthieuDu Cheyron, DamienLambiotte, FabienTamion, FabienneLabruyere, MarieMakris, DemosthenesBoulle Geronimi, ClairePinetonde Chambrun, MarcNyunga, MartinePouly, OlivierMégarbane, BrunoSaade, AnastasiaGomà, GemmaMagira, EleniLlitjos, Jean FrançoisTorres, AntoniIoannidou, IlianaPierre, AlexandreCoelho, LuisReignier, JeanGarot, DenisKreitmann, LouisBaudel, Jean LucVoiriot, GuillaumeContou, DamienBeurton, AlexandraAsfar, PierreBoyer, AlexandreThille, Arnaud W.Mekontso-Dessap, ArmandTsolaki, VassilikiVinsonneau, ChristopheFloch, Pierre EdouardLe Guennec, LoïcCeccato, AdrianArtigas, AntonioBouchereau, MathildeLabreuche, JulienDuhamel, AlainRouzé, AnahitaFavory, RaphaëlPréau, SébastienJourdain, MercéPoissy, JulienLeger, Piehr SaintVan der Linden, ThierryNora, David2021-09-232021-09-232021-08-091364-8535PURE: 33457105PURE UUID: 4e8ca890-f1cf-4010-8202-4ca0544bf0d9Scopus: 85112582450WOS: 000685089200001http://hdl.handle.net/10362/125032Following publication of the original article [1], the authors identified an error in the Abstract and Results section. The correct numbers and text are given hereafter. Abstract VAP was associated with significantly higher risk for 28-day mortality in SARS-CoV-2 group (adjusted HR 1.65 (95% CI 1.11–2.46), p = 0.013), but not in influenza (1.74 (0.99–3.06), p = 0.052), or no viral infection groups (1.13 (0.68–1.86), p = 0.63). Results Primary and secondary outcomes: VAP was associated with higher risk for 28-day mortality in in SARS-CoV-2 group, but not in the two other groups (Fig. 2A). All the changes that were requested are implemented in this correction and the original article [1] has been corrected.585109engCritical Care and Intensive Care Medicineother10.1186/s13054-021-03713-3https://www.scopus.com/pages/publications/85112582450